{"id":"NCT00195819","sponsor":"Abbott","briefTitle":"Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis","officialTitle":"A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-12","primaryCompletion":"2004-10","completion":"2009-06","firstPosted":"2005-09-20","resultsPosted":"2010-04-28","lastUpdate":"2011-06-28"},"enrollment":82,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab (D2E7)","otherNames":["ABT-D2E7","adalimumab","Humira"]},{"type":"BIOLOGICAL","name":"placebo","otherNames":[]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis","primaryOutcome":{"measure":"Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Adalimumab","deltaMin":18,"sd":null},{"arm":"Placebo","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000","p":"0.060"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":9,"countries":["Canada"]},"refs":{"pmids":["21600054","19703304","18050198"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":82},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Ankylosing Spondylitis","Headache","Influenza"]}}